These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27488409)

  • 1. Erratum to: In Vitro Methods for Studying the Mechanisms of Resistance to DNA-Damaging Therapeutic Drugs.
    Khongkow P; Middleton AW; Wong JP; Kandola NK; Kongsema M; de Moraes GN; Gomes AR; Lam EW
    Methods Mol Biol; 2016; 1395():E1. PubMed ID: 27488409
    [No Abstract]   [Full Text] [Related]  

  • 2. In Vitro Methods for Studying the Mechanisms of Resistance to DNA-Damaging Therapeutic Drugs.
    Khongkow P; Middleton AW; Wong JP; Kandola NK; Kongsema M; de Moraes GN; Gomes AR; Lam EW
    Methods Mol Biol; 2016; 1395():39-53. PubMed ID: 26910067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of tolerance to DNA damaging therapeutic drugs.
    Karran P
    Carcinogenesis; 2001 Dec; 22(12):1931-7. PubMed ID: 11751422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling DNA Repair Pathways: Recent Advances and Future Directions.
    Gentile F; Tuszynski JA; Barakat KH
    Curr Pharm Des; 2016; 22(23):3527-46. PubMed ID: 27093954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs.
    Ozaki K; Kishikawa F; Tanaka M; Sakamoto T; Tanimura S; Kohno M
    Cancer Sci; 2008 Feb; 99(2):376-84. PubMed ID: 18201278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin Resistance in Osteosarcoma:
    Fanelli M; Tavanti E; Patrizio MP; Vella S; Fernandez-Ramos A; Magagnoli F; Luppi S; Hattinger CM; Serra M
    Front Oncol; 2020; 10():331. PubMed ID: 32211337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair.
    Hayakawa J; Depatie C; Ohmichi M; Mercola D
    J Biol Chem; 2003 Jun; 278(23):20582-92. PubMed ID: 12663670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARK2 promotes mitochondrial pathway of apoptosis and antimicrotubule drugs chemosensitivity
    Chen H; Li Y; Li Y; Chen Z; Xie L; Li W; Zhu Y; Xue H; Koeffler HP; Wu W; Hu K; Yin D
    Theranostics; 2020; 10(22):9984-10000. PubMed ID: 32929329
    [No Abstract]   [Full Text] [Related]  

  • 9. MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers.
    Plantamura I; Cosentino G; Cataldo A
    Front Oncol; 2018; 8():352. PubMed ID: 30234015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of combi-molecules with DNA-damaging function as anticancer agents.
    Sun G; Fan T; Zhao L; Zhou Y; Zhong R
    Future Med Chem; 2017 Mar; 9(4):403-435. PubMed ID: 28263086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of factors that influence the sensitivity of spores of Bacillus subtilis to DNA damaging chemicals.
    Cortezzo DE; Setlow P
    J Appl Microbiol; 2005; 98(3):606-17. PubMed ID: 15715863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology.
    Cheung-Ong K; Giaever G; Nislow C
    Chem Biol; 2013 May; 20(5):648-59. PubMed ID: 23706631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy.
    Pan Y; Gao Y; Chen L; Gao G; Dong H; Yang Y; Dong B; Chen X
    Clin Cancer Res; 2011 May; 17(10):3248-58. PubMed ID: 21288924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum Resistance in Ovarian Cancer: Role of DNA Repair.
    Damia G; Broggini M
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic AMP (cAMP) confers drug resistance against DNA damaging agents via PKAIA in CML cells.
    Xiao LY; Kan WM
    Eur J Pharmacol; 2017 Jan; 794():201-208. PubMed ID: 27894809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TCTP protein degradation by targeting mTORC1 and signaling through S6K, Akt, and Plk1 sensitizes lung cancer cells to DNA-damaging drugs.
    Jeong M; Jeong MH; Kim JE; Cho S; Lee KJ; Park S; Sohn J; Park YG
    Sci Rep; 2021 Oct; 11(1):20812. PubMed ID: 34675258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells.
    Vella S; Tavanti E; Hattinger CM; Fanelli M; Versteeg R; Koster J; Picci P; Serra M
    PLoS One; 2016; 11(11):e0166233. PubMed ID: 27898692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-resistance mechanisms to DNA-damaging antitumor antibiotics in actinobacteria.
    Tenconi E; Rigali S
    Curr Opin Microbiol; 2018 Oct; 45():100-108. PubMed ID: 29642052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? - A preclinical assessment in vitro and in vivo.
    Briest F; Koziolek EJ; Albrecht J; Schmidt F; Bernsen MR; Haeck J; Kühl AA; Sedding D; Hartung T; Exner S; Welzel M; Fischer C; Grötzinger C; Brenner W; Baum RP; Grabowski P
    Neoplasia; 2021 Jan; 23(1):80-98. PubMed ID: 33246310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New method for studying the kinetics of the excision repair of DNA damages in mammalian cells].
    Filatov MV; Sheĭkina TA
    Tsitologiia; 1984 Apr; 26(4):450-7. PubMed ID: 6740764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.